Screener
McKesson MCK Oncology & Multispecialty — Integration-related cost, expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationIntegrationRelatedCosts.
The source filing: McKesson’s 10-K, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal year
- FY2026
- Accession
- 0000927653-26-000069
- charges of $96 million for the year ended March 31, 2026 related to the acquisition and integration of PRISM Vision and Core Ventures, which were recorded within “Selling, distribution, general, and administrative expenses” in the Company’s Consolidated Statement of Operations;
- a net gain of $51 million for the year ended March 31, 2026 related to the sale of an investment and market decisions, which was recorded within “Selling, distribution, general, and administrative expenses” in the Company’s Consolidated Statement of Operations; and
- a loss of $43 million for the year ended March 31, 2025 related to one of the Company’s equity method investments, which was recorded within “Other income, net” in the Company’s Consolidated Statement of Operations.
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is McKesson's oncology & multispecialty — integration-related cost, expense?
- McKesson (MCK) reported oncology & multispecialty — integration-related cost, expense of $24M in Q1 2026.
- What does oncology & multispecialty — integration-related cost, expense mean?
- Costs incurred to integrate newly acquired businesses into the existing oncology and multispecialty operations. These include expenses for systems migration, personnel alignment, and operational consolidation.
Ask your AI about McKesson's oncology & multispecialty — integration-related cost, expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude